Abstract:Despite advances in the treatment of acute myeloid leukemia (AML), relapse is still widely observed and represents the major cause of death among patients with AML. Treatment options in the relapse setting are limited, still relying predominantly on allogeneic hematopoietic stem cell transplantation (allo-HSCT) and cytotoxic chemotherapy, with poor outcomes. Novel targeted and venetoclax-based combinations are being investigated and have shown encouraging results. Immune checkpoint inhibitors in combination with low-intensity chemotherapy demonstrated encouraging response rates and survival among patients with relapsed and/or refractory (R/R) AML, especially in the pre- and post-allo-HSCT setting. Blocking the CD47/SIRPα pathway is another strategy that showed robust anti-leukemic activity, with a response rate of around 70% and an encouraging median overall survival in patients with newly diagnosed, higher-risk myelodysplastic syndrome and patients with AML with a TP53 mutation. One approach that was proven to be very effective in the relapsed setting of lymphoid malignancies is chimeric antigen receptor (CAR) T cells. It relies on the infusion of genetically engineered T cells capable of recognizing specific epitopes on the surface of leukemia cells. In AML, different CAR constructs with different target antigens have been evaluated and demonstrated safety and feasibility in the R/R setting. However, the difficulty of potently targeting leukemic blasts in AML while sparing normal cells represents a major limitation to their use, and strategies are being tested to overcome this obstacle. A different approach is based on endogenously redirecting the patient’s system cells to target and destroy leukemic cells via bispecific T-cell engagers (BiTEs) or dual antigen receptor targeting (DARTs). Early results have demonstrated the safety and feasibility of these agents, and research is ongoing to develop BiTEs with longer half-life, allowing for less frequent administration schedules and developing them in earlier and lower disease burden settings.

Immunosuppressive microenvironment in acute myeloid leukemia: overview, therapeutic targets and corresponding strategies

Immunotherapies of acute myeloid leukemia: Rationale, clinical evidence and perspective

Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia

Targeting Molecular Signaling Pathways and Cytokine Responses to Modulate c-MYC in Acute Myeloid Leukemia

The Immune Resistance Signature of Acute Myeloid Leukemia and Current Immunotherapy Strategies

Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias

Targeting the Tumor Microenvironment in Acute Myeloid Leukemia: The Future of Immunotherapy and Natural Products

Present and Future Role of Immune Targets in Acute Myeloid Leukemia

A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges

Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development

Updates in novel immunotherapeutic strategies for relapsed/refractory AML

Immunotherapy in leukaemia

Immune-Based Therapeutic Strategies for Acute Myeloid Leukemia

Finding potential targets in cell-based immunotherapy for handling the challenges of acute myeloid leukemia

Targeting the innate immune system in pediatric and adult AML

Epigenetic targeting to enhance acute myeloid leukemia-directed immunotherapy

Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia

Research Advance on the Immune Escape of Acute Myeloid Leukemia——Review

Molecular Markers of Regulatory T Cells in Cancer Immunotherapy with Special Focus on Acute Myeloid Leukemia (AML) - A Systematic Review

Advances in the immunoregulation and cellular immunotherapy in myeloid leukemia

An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!